Reconstituted high-density lipoprotein suppresses leukocyte NADPH oxidase activation by disrupting lipid rafts.
Reconstituted discoidal high-density lipoprotein (rHDL) has potent vascular protective actions. Native HDL suppresses cellular generation of reactive oxygen species, whereas this antioxidant effect of rHDL is less clear. This study examined the effects of rHDL on NADPH oxidase, a major source of cellular superoxide generation, in both leukocytes and human umbilical vein endothelial cells. Superoxide was measured with lucigenin-enhanced chemiluminescence. Expression of NADPH oxidase sub-units was determined by real-time PCR. Pre-treatment of HL-60 cells with rHDL (10 and 25 microM) for 1 h significantly reduced phorbol 12-myristate 13-acetate-stimulated superoxide production. Treatment with rHDL for up to 24 h did not change the mRNA expression of NADPH oxidase sub-units. In HL-60 cells, depletion of cholesterol from the plasma membrane by methyl-beta-cyclodextrin mimicked the effect of rHDL, whereas cholesterol repletion blunted the effects of rHDL. Treatment with rHDL induced disruption of the lipid raft structures and blunted PMA-induced redistribution of p47phox into lipid rafts. In contrast, treatment of endothelial cells with rHDL for up to 18 h had no effect on either basal or tumour necrosis factor-alpha-stimulated NADPH oxidase activity, but markedly suppressed the cytokine-induced expression of proinflammatory adhesion molecules. The results suggest that rHDL inhibits NADPH oxidase activation in leukocytes, probably by interrupting the assembly of NADPH oxidase sub-units at the lipid rafts. This effect may contribute to the vascular protective actions of rHDL against inflammation-mediated oxidative damage.
Peshavariya
Hitesh
H
Bernard O'Brien Institute of Microsurgery, University of Melbourne, Victoria, Australia.
Dusting
Gregory J
GJ
Di Bartolo
Belinda
B
Rye
Kerry-Anne
KA
Barter
Philip J
PJ
Jiang
Fan
F
D016632:Apolipoprotein A-I / Q000494:pharmacology; D002474:Cell-Free System; D002784:Cholesterol / Q000378:metabolism; D042783:Endothelial Cells / Q000187:drug effects* / Q000378:metabolism / Q000648:ultrastructure; D004789:Enzyme Activation / Q000187:drug effects; D018922:HL-60 Cells / Q000187:drug effects / Q000378:metabolism / Q000648:ultrastructure; D006801:Humans; D007962:Leukocytes / Q000187:drug effects* / Q000378:metabolism / Q000648:ultrastructure; D008075:Lipoproteins, HDL / Q000494:pharmacology*; D008163:Luminescent Measurements; D008563:Membrane Lipids / Q000378:metabolism; D021962:Membrane Microdomains / Q000187:drug effects*; D019255:NADPH Oxidases / Q000037:antagonists & inhibitors*; D010587:Phagocytosis / Q000187:drug effects; D010713:Phosphatidylcholines / Q000494:pharmacology; D013481:Superoxides / Q000378:metabolism; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D014471:Umbilical Veins; D019820:Xanthine / Q000378:metabolism; D014969:Xanthine Oxidase / Q000378:metabolism; D047392:beta-Cyclodextrins / Q000494:pharmacology
D016632:Apolipoprotein A-I; D008075:Lipoproteins, HDL; D008563:Membrane Lipids; D010713:Phosphatidylcholines; D047392:beta-Cyclodextrins; C108732:methyl-beta-cyclodextrin; D013481:Superoxides; D019820:Xanthine; C055402:1-palmitoyl-2-linoleoylphosphatidylcholine; D002784:Cholesterol; D014969:Xanthine Oxidase; D019255:NADPH Oxidases; D013755:Tetradecanoylphorbol Acetate